Peter Lynch · Growth at a reasonable price (GARP)
Is Regeneron Pharmaceuticals, Inc. (REGN) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria, growth too low or price too high.
24/100
No encaja
3/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a REGN
PEG ≤ 1.0
clave-
EPS CAGR ≥ 15%
clave-13.3%
Revenue CAGR ≥ 10%
-2.8%
Net margin > 0
29.6%
Cómo se valora REGN en otras estrategias
Datos financieros en vivo
Cap. mercado
$74.79B
PER (TTM)
16.4x
ROIC (TTM)
8.53%
Margen bruto
84.55%
Otros análisis Peter Lynch
Preguntas frecuentes
What is REGN's Peter Lynch fit score?
REGN scores 24/100 on our Peter Lynch fit engine. Does not fit Lynch's GARP criteria, growth too low or price too high.
Does Peter Lynch actually own REGN?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends REGN.
How often is this score updated?
REGN's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende REGN personalmente.
